JY
VRDN icon

Jeff Yass’s Viridian Therapeutics VRDN Stock Holding History

Jeff Yass’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$911K Sell
49,600
-183,700
-79% -$2.96M ﹤0.01% 8423
2026
Q1 		$4.56M Buy
233,300
+216,900
+1,323% +$6.44M ﹤0.01% 4394
2025
Q4 		$510K Sell
16,400
-31,200
-66% -$856K ﹤0.01% 8738
2025
Q3 		$1.03M Sell
47,600
-184,100
-79% -$3.32M ﹤0.01% 7299
2025
Q2 		$3.24M Buy
231,700
+221,600
+2,194% +$3.01M ﹤0.01% 4817
2025
Q1 		$136K Sell
10,100
-201,000
-95% -$3.42M ﹤0.01% 11303
2024
Q4 		$4.05M Buy
211,100
+111,600
+112% +$2.43M ﹤0.01% 3929
2024
Q3 		$2.26M Buy
99,500
+76,100
+325% +$1.24M ﹤0.01% 5034
2024
Q2 		$304K Buy
23,400
+2,200
+10% +$30.5K ﹤0.01% 9410
2024
Q1 		$371K Buy
21,200
+7,600
+56% +$147K ﹤0.01% 9207
2023
Q4 		$296K Buy
+13,600
New +$215K ﹤0.01% 9869
2023
Q3 		– Sell
-244,500
Closed -$5.82M – 13086
2023
Q2 		$5.82M Buy
244,500
+228,900
+1,467% +$5.87M ﹤0.01% 3287
2023
Q1 		$397K Buy
+15,600
New +$500K ﹤0.01% 9113
2022
Q4 		– Sell
-27,300
Closed -$560K – 13782
2022
Q3 		$560K Buy
+27,300
New +$491K ﹤0.01% 8191

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Jeff Yass's VRDN Position: Q2 2026 in Review

Jeff Yass increased its Viridian Therapeutics (VRDN) stake by 140% in Q2 2026, buying an estimated $1.22M and bringing the position to 130,284 shares worth $2.39M. The position accounts for ﹤0.01% of the portfolio, ranked #6079.

Jeff Yass first reported a position in VRDN in Q1 2015 and has held it in 23 quarters since. The position peaked at $5M in Q2 2023. 212 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Jeff Yass held 130,284 shares of Viridian Therapeutics worth $2.39M as of Q2 2026.
  • Jeff Yass bought 76,007 Viridian Therapeutics shares in Q2 2026, an estimated $1.22M.
  • Viridian Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #6079 holding.
  • Jeff Yass first reported a position in Viridian Therapeutics in Q1 2015 and has held it in 23 quarters since.
  • Jeff Yass's Viridian Therapeutics position peaked at $5M in Q2 2023.
  • 212 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.